Cadence raises $100M Series C led by Spark Capital
Cadence secured $100 million in Series C funding led by Spark Capital to scale its AI-driven chronic care platform. The company, treating 100,000 patients, tripled revenue in 2025 and reported significant clinical outcomes including reduced hospital admissions and lower care costs. New affiliations with Duke Health and Texas Health Resources expand its reach to over 20 health systems.

*this image is generated using AI for illustrative purposes only.
Cadence, a clinical AI company managing chronic care for older adults, raised $100 million in a Series C funding round led by Spark Capital. The investment aims to scale AI agents to address the needs of over 56 million older adults with chronic disease amid a deepening clinician shortage. Cadence treats more than 100,000 active patients and tripled its annual recurring revenue in 2025.
The round included participation from Thrive Capital, General Catalyst, Coatue, B Capital, Corewell Health Ventures, Memorial Hermann, and Duke Health. Will Reed, partner at Spark Capital, will join Cadence's board. The company announced new affiliations with Duke Health and Texas Health Resources, expanding its partnerships to over 20 leading health systems.
Cadence's Clinical Intelligence integrates directly into partner health systems' electronic medical records and clinical workflows. Supervised AI agents monitor patient vitals daily, support medication adjustments, and provide lifestyle coaching. The system reports a median response time of 3.5 minutes for incoming vitals alerts, with 55% resolved without human adjustment.
The company's model has demonstrated significant clinical outcomes and cost savings. Peer-reviewed studies indicate a 230% increase in heart failure patients on guideline-directed medical therapy and a 70% relative increase in blood pressure control for hypertension patients. Additionally, the model achieved a 27% reduction in hospital admissions and a $1,302 per-patient annual reduction in total cost of care.
Cadence's Remote Patient Care model returns more than $3 to Medicare for every dollar spent, saving the program roughly $2.7 million weekly. With the new capital, Cadence plans to expand across new health systems, advance its AI agents, and grow value-based care models.
How will Cadence leverage the new capital to navigate potential regulatory hurdles as its AI agents take on more autonomous clinical responsibilities?
With the expansion to over 20 health systems, what strategies will Cadence employ to maintain consistent clinical outcomes across diverse patient populations?
As the company scales, how might the increasing reliance on AI agents impact the traditional roles and workflow of remaining human clinicians?



























